Cargando…

Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial

Bruton’s tyrosine kinase (BTK) is crucial for FcεRI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. This doubl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metz, Martin, Sussman, Gordon, Gagnon, Rémi, Staubach, Petra, Tanus, Tonny, Yang, William H., Lim, Jeremy J., Clarke, Holly J., Galanter, Joshua, Chinn, Leslie W., Chu, Tom, Teterina, Anastasia, Burgess, Tracy, Haddon, D. James, Lu, Timothy T., Maurer, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604722/ https://www.ncbi.nlm.nih.gov/pubmed/34750553 http://dx.doi.org/10.1038/s41591-021-01537-w

Ejemplares similares

Pathobiology of Second-Generation Antihistamines Related to Sleep in Urticaria Patients
por: Mann, Caroline, et al.
Publicado: (2022)

Understanding the Effect of Hydroxypropyl‐β‐Cyclodextrin on Fenebrutinib Absorption in an Itraconazole–Fenebrutinib Drug–Drug Interaction Study
por: Durk, Matthew R., et al.
Publicado: (2020)

Hyperresponsiveness to antihistamines in spontaneous urticaria and heat urticaria
por: Durda, J., et al.
Publicado: (2017)

Efficacy of Second-Line Treatments in Chronic Urticaria Refractory to Standard Dose Antihistamines
por: Kim, Mi-Ae, et al.
Publicado: (2023)

CSACI position statement: Newer generation H(1)-antihistamines are safer than first-generation H(1)-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria
por: Fein, Michael N., et al.
Publicado: (2019)

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI
por: Jones, Nicholas S., et al.
Publicado: (2019)

Features of Antihistamine-Resistant Chronic Urticaria and Chronic Urticaria During Exacerbation
por: Huilan, Zhu, et al.
Publicado: (2015)

H(1)-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients' Perspective of Effectiveness and Side Effects – A Retrospective Survey Study
por: Weller, Karsten, et al.
Publicado: (2011)

Treating chronic urticaria refractory to H1-antihistamines in Russia: data from the AWARE study
por: Danilycheva, Inna, et al.
Publicado: (2022)

Bepotastine-induced urticaria, cross-reactive with other antihistamines
por: Kang, Ju Wan, et al.
Publicado: (2016)

Drug eruption by antihistamine mistaken for chronic urticaria in a child
por: Lee, Gun Moo, et al.
Publicado: (2019)

Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study
por: Ulambayar, Bastsetseg, et al.
Publicado: (2019)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
por: Chen, Yuan, et al.
Publicado: (2020)

Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
por: Chan, Phyllis, et al.
Publicado: (2020)

How to use antihistamines
por: Chu, Derek K., et al.
Publicado: (2021)

Autologous Serum Therapy in Chronic Urticaria: A Promising Complement to Antihistamines
por: Debbarman, Panchami, et al.
Publicado: (2014)

Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria
por: Sánchez-Borges, Mario, et al.
Publicado: (2014)

Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia
por: Recto, Marysia Tiongco, et al.
Publicado: (2017)

The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 2. Management of H1-Antihistamine-Refractory Chronic Urticaria
por: Choi, Jeong-Hee, et al.
Publicado: (2020)

Autologous Whole Blood Injection for the Treatment of Antihistamine-Resistant Chronic Spontaneous Urticaria
por: You, Hyang-Suk, et al.
Publicado: (2015)

Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine
por: Wang, Xue Yan, et al.
Publicado: (2016)

Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria
por: van den Elzen, Mignon T., et al.
Publicado: (2017)

Autologous serum therapy reduces the symptoms and antihistamine burden in patients with chronic urticaria
por: Mohammed, Jinan Q.
Publicado: (2023)

Comparing azathioprine with cyclosporine in the treatment of antihistamine refractory chronic spontaneous urticaria: A randomized prospective active-controlled non-inferiority study()
por: Pathania, Yashdeep Singh, et al.
Publicado: (2019)

The influence of hepatitis C virus infection on H1 antihistamine treatment in urticaria patients
por: Dinu, Lucia, et al.
Publicado: (2014)

Evidence Gaps in Clinical Trials of Pharmacologic Treatment for H1-Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Future Perspectives
por: Nochaiwong, Surapon, et al.
Publicado: (2022)

Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial
por: Cohen, Stanley, et al.
Publicado: (2020)

Expert consensus on practical aspects in the treatment of chronic urticaria
por: Bauer, Andrea, et al.
Publicado: (2021)

Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria
por: Kolkhir, Pavel, et al.
Publicado: (2021)

Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data
por: Staubach, P., et al.
Publicado: (2017)

In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria
por: Moñino‐Romero, Sherezade, et al.
Publicado: (2023)

Investigation of Fenebrutinib Metabolism and Bioactivation Using MS(3) Methodology in Ion Trap LC/MS
por: Alsibaee, Aishah M., et al.
Publicado: (2023)

Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review
por: Di Lorenzo, Gabriele, et al.
Publicado: (2008)

Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria
por: Wolthers, Ole D.
Publicado: (2013)

Compound glycyrrhizin combined with antihistamines for chronic urticaria: A protocol for systematic review and meta analysis
por: Cao, Wei, et al.
Publicado: (2020)

High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab
por: Madsen, Hanne, et al.
Publicado: (2021)

Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H(1)-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC study
por: Chu, Chia-Yu, et al.
Publicado: (2020)

Up-dosing of non-sedating antihistamines in chronic urticaria: Need for well-designed clinical trials in India
por: Patil, Anant D.
Publicado: (2014)

The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the Vietnamese Experience
por: Thi, Huyen Tran, et al.
Publicado: (2019)

A protocol for the development and internal validation of a model to predict clinical response to antihistamines in urticaria patients
por: Sanchez, Jorge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hst81erpib9c95ujgp3bkqs6eq